Wednesday, October 14, 2026

Nikkei 225 Went Up By Over 5% In The Last 21 Sessions

ViaNews Editorial Team

February 8, 2024

Nikkei 225 Went Up By Over 5% In The Last 21 Sessions

(VIANEWS) - Nikkei 225 (N225) has been up by 5.57% for the last 21 sessions. At 20:08 EST on Wednesday, 7 February, Nikkei 225 (N225) is $36,358.91.

Concerning Nikkei 225's yearly highs and lows, it's 36.52% up from its 52-week low and 1.69% down from its 52-week high.

Volatility

Nikkei 225's last week, last month's, and last quarter's current intraday variation average was 0.08%, 0.36%, and 0.76%, respectively.

Nikkei 225's highest amplitude of average volatility was 0.40% (last week), 0.81% (last month), and 0.76% (last quarter), respectively.

Index Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Nikkei 225's is considered to be overbought (>=80).

News about

  • According to Zacks on Tuesday, 6 February, "Despite a rebound in stocks with the Dow and S&P 500 hitting new all-time highs, PDS shares have not been participating lately. ", "PDS shares have fallen more than 30% since the S&P 500 bottomed out back in late 2022."
  • According to Zacks on Tuesday, 6 February, "View all Key Company Metrics for Envista here>>>Envista shares have witnessed a change of -1.2% in the past month, in contrast to the Zacks S&P 500 composite's +5.3% move. "
  • According to DailyForex on Tuesday, 6 February, "In the United States, the Dow Jones and S&P 500 indices dropped by more than 1% on Monday. "
  • According to DailyForex on Tuesday, 6 February, "It is crucial to bear in mind that the S&P 500 is primarily influenced by a select few stocks, often referred to as the "magnificent seven." These stocks exert substantial sway over the broader index, reflecting the impact of passive investing on the S&P 500's composition.", "During the early hours of Monday's trading session, the S&P 500 displayed a tranquil demeanor. "

More news about Nikkei 225 (N225).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com